SELLAS Life Sciences Group, Inc.
Every calculator, already run for SLS
Open the full toolkit →You have the numbers on SLS. Get the argument.
A written report on which of these readings actually decide the outcome for SELLAS Life Sciences Group, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
2 analysts covering SLSAnalyst Price Target Disagreement for SELLAS Life Sciences Group, Inc.
Wall Street's bull case implies +251% from the current price; the bear case implies +201%. A 50% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for SLS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet…
SLS — frequently asked
Is SLS a buy right now?
Wall Street's consensus rating on SELLAS Life Sciences Group, Inc. is none across 2 analysts, with a mean price target of $32.50 (+226% vs. the current $9.98). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is SLS's next earnings date?
SELLAS Life Sciences Group, Inc. is next scheduled to report earnings around Nov 11, 2026. A full SLS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for SELLAS Life Sciences Group, Inc.?
Analysts covering SELLAS Life Sciences Group, Inc. (SLS) range from a bear-case target of $30.00 to a bull-case high of $35.00, with a mean consensus target of $32.50 across 2 analysts. The spread of $5.00 (50% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare SELLAS Life Sciences Group, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For SELLAS Life Sciences Group, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full SLS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on SELLAS Life Sciences Group, Inc., in minutes. 3 free reports included with every account — no credit card required.